Drug Safety Panel Urges New Entity To Oversee Japan Drug Approvals
This article was originally published in PharmAsia News
Executive Summary
TOKYO - An ad hoc study commission debating prevention of recurring drug-induced hepatitis and HIV infections has recommended creating an independent entity that would supervise pharmaceutical approvals, drug safety and adverse events in an effort to toughen Japanese new drug approval processes
You may also be interested in...
Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)
Banyu Pharmaceutical, a Japanese company established in 1915, after its founder discovered a remedy for syphilis, became a wholly owned subsidiary of Merck in 2004. Since then, Banyu has had a somewhat unique position in Japan as an affiliate of a global pharma company, but with strong Japanese roots. Elizabeth Cobbs, Banyu's senior director of public and industry policy, sat down with PharmAsia News' Tokyo bureau to discuss the company's strategic outlook and regulatory challenges.
Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)
Banyu Pharmaceutical, a Japanese company established in 1915, after its founder discovered a remedy for syphilis, became a wholly owned subsidiary of Merck in 2004. Since then, Banyu has had a somewhat unique position in Japan as an affiliate of a global pharma company, but with strong Japanese roots. Elizabeth Cobbs, Banyu's senior director of public and industry policy, sat down with PharmAsia News' Tokyo bureau to discuss the company's strategic outlook and regulatory challenges.
India Price Regulator Wants At Least Five Drug Makers Charged
India's regulator of drug prices has called for legal action against five pharmaceutical companies on charges they violated price controls. The National Pharmaceutical Pricing Authority said the companies collectively sold 39 specified pack sizes of different drugs without prior approval of the prices. The firms named were Alembic, Cadilla Healthcare, Medley Pharmaceuticals, Lupin and Wockhardt. The NPPA said it also is looking at nearly 30 other cases of alleged overcharges and is asking the firms involved to repay the excess amounts. It asked state governments to begin prosecution proceedings. (Click here for more